Ignite Creation Date:
2024-05-06 @ 3:21 AM
Last Modification Date:
2024-10-26 @ 11:33 AM
Study NCT ID:
NCT02278588
Status:
COMPLETED
Last Update Posted:
2023-02-14
First Post:
2014-10-28
Brief Title:
Effect of 25 Years of Rasagiline Therapy on Progression of Cognitive Biomarkers Assessed by MRI in Parkinsons Disease
Sponsor:
State University of New York at Buffalo
Organization:
State University of New York at Buffalo
Study Overview
Official Title:
Effect of 25 Years of Rasagiline Therapy on Progression of Cognitive Biomarkers Assessed by MRI in Parkinsons Disease
Status:
COMPLETED
Status Verified Date:
2023-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In this investigator-initiated study we will compare changes in brain cognitive biomarkers assessed by diffusion tensor imaging over 25 years among 12 patients with Idiopathic Parkinsons disease IPD receiving rasagiline 20 IPD patients not receiving MAO-B inhibitors and 25 age-matched healthy controls Will also compare the changes in Mini-Mental State Exam MMSE and Montreal Cognitive Assessment MoCA scores and plasma brain-derived neurotrophic factor BDNF with changes in brain cognitive biomarkers in all IPD patients and HC over 25 years
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None